Early-Phase Oncology ePRO Solution: Complete Tolerability Assessment
Targeted treatments often show efficacy below maximum tolerated dose, making the patient perspective a vital component for characterizing dose-tolerability relationships as well as selecting optimal doses for later phases. Tolerability evidence is incomplete without patient-reported adverse events data.
Signant's pre-configured ePRO solution is purpose-built for the speed and accuracy early-phase oncology research demands, providing:
✓ Rapid out-of-the-box implementation for early-phase speed requirements
✓ Comprehensive tolerability assessment with validated PRO-CTCAE measures (78 AEs) plus impact assessments
✓ Frequent assessment schedules for complete insights
✓ BYOD efficiencies with provisioned device options
✓ Real-time compliance monitoring to ensure complete datasets
Why choose ePRO over paper?
- Assured data quality with timely completion tracking
- Remote patient oversight between clinic visits
- Simplified navigation through complex PRO-CTCAE
- Electronic free-text capture reduces data management burden
- Competitively priced for early-phase budgets
Take a look at our brochure for more details, and contact us if you'd like to discuss your oncology PRO strategy with experts who understand your oncology indication.
